Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has announced that the Phase 3 KEYFORM-007 trial, which investigated the fixed-dose combination of favezelimab (Merck’s anti-LAG-3 antibody) and pembrolizumab (KEYTRUDA®), did not meet its primary goal of improving…
BioAlberta is excited to announce a new partnership with AxialBridge as its operational and commercialization partner. This collaboration aims to assist Alberta-based biotechnology and MedTech companies in expanding their clinical and research efforts into the United Kingdom. With the launch…
Tennessee Governor Bill Lee, along with Economic and Community Development Commissioner Stuart C. McWhorter and Harrow, Inc. CEO Mark L. Baum, announced today that Harrow is expanding its corporate headquarters in Nashville. Originally founded in San Diego, California, in 2012,…
Medidata, a Dassault Systèmes brand and a leader in clinical trial solutions for the life sciences industry, has introduced Medidata Patient Payments, a new solution designed to simplify the process of providing stipends and reimbursements to patients involved in clinical…
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced the launch of its new cobas® Respiratory flex test, the first to incorporate Roche’s proprietary TAGS (Temperature-Activated Generation of Signal) technology. This innovative technology, developed by Roche scientists, enhances multiplex polymerase chain…
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), proudly announces the next chapter of its 2024 BOTOX® Cosmetic grant program, focused on empowering women entrepreneurs. This phase introduces crowdfunding campaigns for each of the 20 grant recipients, providing the public…
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharmaceutical company dedicated to developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders, has released its interim financial results for the first half of 2024, along…
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the phase III CENTERSTONE study of Xofluza® (baloxavir marboxil), an antiviral medication, demonstrating a significant reduction in the transmission of influenza viruses. The study successfully met its primary…
Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (“Cybin” or the “Company”), a clinical-stage neuropsychiatry company focused on advancing mental healthcare through innovative, next-generation treatments, recently shared key clinical accomplishments and outlined its upcoming milestones. “We’re making significant progress in…
Neuraptive Therapeutics, a biopharmaceutical leader specializing in innovative treatments for peripheral nerve injuries, has announced that interim topline results from their ongoing Phase 2 NEUROFUSE study will be presented at the 2024 American Society for Surgery of the Hand (ASSH)…
Alzprotect, a French biopharmaceutical company, has successfully completed the open-label extension (OLE) phase following its Phase 2a clinical trial of AZP2006 (ezeprogind®), a treatment for Progressive Supranuclear Palsy (PSP). The results of this 6-month extension highlight the potential of AZP2006…
Viatris Inc. (NASDAQ: VTRS, “Viatris” or the “Company”) today announced the early results of its subsidiary Utah Acquisition Sub Inc.’s (“UAS”) previously announced cash tender offer (the “Maximum Tender Offer”). UAS has increased the maximum aggregate principal amount for the…